InSphero AG and Cosmo Bio Co., Ltd Enter into Partnership to Distribute InSphero’s Innovative Product Portfolio in Japan

August 02, 2023 12:50 PM BST | By EIN Presswire
 InSphero AG and Cosmo Bio Co., Ltd Enter into Partnership to Distribute InSphero’s Innovative Product Portfolio in Japan
Image source: Kalkine Media

InSphero AG and Cosmo Bio Co., Ltd Enter into Strategic Partnership to Distribute InSphero’s Innovative Product Portfolio in Japan

ZURICH, ZURICH, SWITZERLAND, August 2, 2023/EINPresswire.com/ -- InSphero AG and Cosmo Bio Co., Ltd. are announcing a strategic partnership to distribute InSphero’s innovative product portfolio in Japan. This alliance, effective immediately, will see Cosmo Bio becoming the exclusive distributor of InSphero’s 3D cell-based assay solutions across the Japanese market.

InSphero, a global pioneer in 3D cell culture and organ-on-chip technology, is known for its advanced 3D microtissues and assay services. It is widely employed by pharmaceutical, chemical, and cosmetic industries for more accurate, cost-effective testing of new substances and ingredients.

With its vast network and experience in life science product distribution, Cosmo Bio will allow the Swiss biotech company to deepen its footprint in the vital Japanese market.

Paul Clémençon, Head of Business Development at InSphero, says: “We are thrilled about our partnership with Cosmo Bio. Their reputation as a leading supplier of life sciences reagents and instruments in Japan is impeccable. We firmly believe this collaboration will significantly boost the availability and adoption of our innovative 3D cell-based assay solutions in Japan. It’s a momentous day for us at InSphero as we continue to scale our international operations.”

The Cosmo Bio team echoes this excitement. Haruhisa Sakurai, Ph.D., CEO and President of Cosmo Bio, remarks: “InSphero’s products embody a leap forward in biotechnology. We are eager to distribute their leading-edge 3D cell culture technology to our customers. It is a privilege to partner with a company that shares our commitment to scientific innovation and customer satisfaction.”

Both companies anticipate that this partnership will significantly benefit researchers and enterprises in Japan, enabling them to access world-class 3D microtissue models for drug development, safety testing, and disease modeling.

# # # #

About Cosmo Bio
Cosmo Bio is an organization established to sell and distribute biological reagents and services for the biotechnology market including biopharmaceutical applications studies, headquartered in Tokyo, with a network of over 200 contracted dealers throughout Japan. Cosmo Bio is one of the largest and most established life sciences reagents and services suppliers in Japan.

About InSphero
InSphero is the only 3D in vitro model company with the platform and expertise to modernize drug discovery in a way that empowers researchers to reach their full potential. Our innovative spheroid-based models allow more effective, safe therapies to contact the clinic through superior robustness, reliability, reproducibility, and scalability. InSphero’s goal is to inspire the next generation of breakthrough therapies through customer obsession, commitment to innovation, and the model of excellence.

Learn more at insphero.com. Follow the company on LinkedIn and sign up for the Scientific Newsletter.

Media Contacts

Cosmo Bio
Norihiko Shibayama
[email protected]

Paul Clémençon
InSphero
+41 44 515 04 90
[email protected]
Visit us on social media:
Facebook
Twitter
LinkedIn


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next